Ownership history in Stonepine Capital Management, LLC Β· 3 quarters on record
This page tracks every 13F SEC filing in which Stonepine Capital Management, LLC reported a position in EDESA BIOTECH INC (EDSA). Data includes quarterly share count, position size as % of portfolio, estimated market value, and end-of-quarter stock price β sourced directly from SEC EDGAR 13F filings.
π Stonepine Capital Management, LLC underperformed the S&P 500 by β127.4% annually on this EDSA position. Average cost basis: $2.44. Maximum drawdown during holding period: β42.5%.
β Significantly underperformed the S&P 500 by 127.4% ann.
2 quarters analyzed
Best entry: $2.44 (2025 Q1) Β· Worst: $2.44 (2025 Q1)
πͺ Held through 1 major drawdown (>20%). Strong conviction under pressure.
1 add Β· 0 trims. Bought during 0 of 1 down-price quarters. π Consistently bullish β fund kept accumulating this position.
π Portfolio weight has been declining in recent quarters. Possible distribution phase.
Currently 0.71% of portfolio
β Based on quarterly 13F SEC filings and end-of-quarter closing prices. Timing score = accuracy of add/trim decisions vs next-quarter price direction. Alpha = mean quarterly excess return Γ 4 (annualised). Not investment advice.
As of 2025 Q4 β sorted by position size